vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $281.3M, roughly 1.3× Guardant Health, Inc.). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs -45.7%, a 77.3% gap on every dollar of revenue. Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 19.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
GH vs PB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $367.6M |
| Net Profit | $-128.5M | $116.3M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 31.6% |
| Revenue YoY | 39.4% | — |
| Net Profit YoY | -15.8% | -10.7% |
| EPS (diluted) | $-1.01 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $367.6M | ||
| Q4 25 | $281.3M | $275.0M | ||
| Q3 25 | $265.2M | $273.4M | ||
| Q2 25 | $232.1M | $267.7M | ||
| Q1 25 | $203.5M | $265.4M | ||
| Q4 24 | $201.8M | $267.8M | ||
| Q3 24 | $191.5M | $261.7M | ||
| Q2 24 | $177.2M | $258.8M |
| Q1 26 | — | $116.3M | ||
| Q4 25 | $-128.5M | $139.9M | ||
| Q3 25 | $-92.7M | $137.6M | ||
| Q2 25 | $-99.9M | $135.2M | ||
| Q1 25 | $-95.2M | $130.2M | ||
| Q4 24 | $-111.0M | $130.1M | ||
| Q3 24 | $-107.8M | $127.3M | ||
| Q2 24 | $-102.6M | $111.6M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | 65.1% | ||
| Q3 25 | -37.3% | 64.4% | ||
| Q2 25 | -45.9% | 64.3% | ||
| Q1 25 | -54.6% | 62.7% | ||
| Q4 24 | -62.4% | 62.0% | ||
| Q3 24 | -61.3% | 62.1% | ||
| Q2 24 | -56.8% | 55.2% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | -45.7% | 50.9% | ||
| Q3 25 | -35.0% | 50.3% | ||
| Q2 25 | -43.0% | 50.5% | ||
| Q1 25 | -46.8% | 49.1% | ||
| Q4 24 | -55.0% | 48.6% | ||
| Q3 24 | -56.3% | 48.6% | ||
| Q2 24 | -57.9% | 43.1% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $-1.01 | $1.48 | ||
| Q3 25 | $-0.74 | $1.45 | ||
| Q2 25 | $-0.80 | $1.42 | ||
| Q1 25 | $-0.77 | $1.37 | ||
| Q4 24 | $-0.90 | $1.36 | ||
| Q3 24 | $-0.88 | $1.34 | ||
| Q2 24 | $-0.84 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $8.2B |
| Total Assets | $2.0B | $43.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | — | ||
| Q3 25 | $580.0M | — | ||
| Q2 25 | $629.1M | — | ||
| Q1 25 | $698.6M | — | ||
| Q4 24 | $525.5M | — | ||
| Q3 24 | $585.0M | — | ||
| Q2 24 | $933.7M | — |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $-99.3M | $7.6B | ||
| Q3 25 | $-354.5M | $7.7B | ||
| Q2 25 | $-305.5M | $7.6B | ||
| Q1 25 | $-250.8M | $7.5B | ||
| Q4 24 | $-139.6M | $7.4B | ||
| Q3 24 | $-60.1M | $7.4B | ||
| Q2 24 | $-1.6M | $7.3B |
| Q1 26 | — | $43.6B | ||
| Q4 25 | $2.0B | $38.5B | ||
| Q3 25 | $1.3B | $38.3B | ||
| Q2 25 | $1.3B | $38.4B | ||
| Q1 25 | $1.3B | $38.8B | ||
| Q4 24 | $1.5B | $39.6B | ||
| Q3 24 | $1.5B | $40.1B | ||
| Q2 24 | $1.6B | $39.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $78.3M | ||
| Q3 25 | $-35.4M | $194.8M | ||
| Q2 25 | $-60.3M | $98.2M | ||
| Q1 25 | $-62.7M | $178.2M | ||
| Q4 24 | $-64.5M | $-205.8M | ||
| Q3 24 | $-51.1M | $274.6M | ||
| Q2 24 | $-94.0M | $216.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $68.5M | ||
| Q3 25 | $-45.8M | $185.7M | ||
| Q2 25 | $-65.9M | $91.8M | ||
| Q1 25 | $-67.1M | $171.1M | ||
| Q4 24 | $-83.4M | $-210.7M | ||
| Q3 24 | $-55.3M | $270.2M | ||
| Q2 24 | $-99.1M | $211.8M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 24.9% | ||
| Q3 25 | -17.3% | 67.9% | ||
| Q2 25 | -28.4% | 34.3% | ||
| Q1 25 | -33.0% | 64.5% | ||
| Q4 24 | -41.3% | -78.7% | ||
| Q3 24 | -28.9% | 103.3% | ||
| Q2 24 | -55.9% | 81.8% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 3.6% | ||
| Q3 25 | 3.9% | 3.3% | ||
| Q2 25 | 2.4% | 2.4% | ||
| Q1 25 | 2.2% | 2.7% | ||
| Q4 24 | 9.4% | 1.8% | ||
| Q3 24 | 2.2% | 1.7% | ||
| Q2 24 | 2.9% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 1.42× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 1.37× | ||
| Q4 24 | — | -1.58× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
